ArticleThe oncologist2021

Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma.

Yong Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.